

# Program Memorandum Carriers

Department of Health and  
Human Services (DHHS)  
HEALTH CARE FINANCING  
ADMINISTRATION (HCFA)

Transmittal B-00-38

Date: AUGUST 7, 2000

## CHANGE REQUEST 1262

**SUBJECT: Addition of “WW” Codes to Identify a New Source for an Oral Anti-Cancer Drug in Dosages of 25mg and 100mg**

These two new codes must be included in the DMERC, VIPS, and CWF systems in order to adjudicate claims for the oral anti-cancer drug listed below.

WW014 – Cyclophosphamide (Roxane), 25mg, oral (NDC #00054-4129-25)

WW015 – Cyclophosphamide (Roxane), 50mg, oral (NDC #00054-4130-25)

(DMEPOS category:9)(CWF category:17,60)(POS: 12,31,32,33,54,55,56)(TOS:9)

**\*\*NOTE:** The “WW” codes are used for DMERC internal systems only. Providers should still bill using the appropriate NDC codes for oral anti-cancer drugs.

**\*\*\*The approval date for Medicare coverage of this drug was June 1, 2000.**

**The *effective date* for this Program Memorandum (PM) is October 1, 2000.**

**The *implementation date* for this PM is October 1, 2000.**

**These instructions should be implemented within your current operating budget.**

**This PM may be discarded after October 1, 2001.**

**If you have any questions, contact Angie Costello at 410-786-1554 or (acostello@hcfa.gov).**